These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8226814)

  • 21. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catalytic antibody model and mutagenesis implicate arginine in transition-state stabilization.
    Roberts VA; Stewart J; Benkovic SJ; Getzoff ED
    J Mol Biol; 1994 Jan; 235(3):1098-116. PubMed ID: 8289310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical interactions in binding antibody NC41 to influenza N9 neuraminidase: amino acid contacts on the antibody heavy chain.
    Pruett PS; Air GM
    Biochemistry; 1998 Jul; 37(30):10660-70. PubMed ID: 9692956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides.
    McCartney JE; Tai MS; Hudziak RM; Adams GP; Weiner LM; Jin D; Stafford WF; Liu S; Bookman MA; Laminet AA
    Protein Eng; 1995 Mar; 8(3):301-14. PubMed ID: 7479692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Residues flanking the COOH-terminal C-region of a model eukaryotic signal peptide influence the site of its cleavage by signal peptidase and the extent of coupling of its co-translational translocation and proteolytic processing in vitro.
    Nothwehr SF; Hoeltzli SD; Allen KL; Lively MO; Gordon JI
    J Biol Chem; 1990 Dec; 265(35):21797-803. PubMed ID: 2123875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Random mutagenesis of two complementarity determining region amino acids yields an unexpectedly high frequency of antibodies with increased affinity for both cognate antigen and autoantigen.
    Casson LP; Manser T
    J Exp Med; 1995 Sep; 182(3):743-50. PubMed ID: 7650481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A functional antibody mutant with an insertion in the framework region 3 loop of the VH domain: implications for antibody engineering.
    Simon T; Rajewsky K
    Protein Eng; 1992 Apr; 5(3):229-34. PubMed ID: 1409542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in antigen-binding affinity caused by a single amino acid substitution in the variable region of the heavy chain.
    Xiang J; Chen Z; Delbaere LT; Liu E
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():239-47. PubMed ID: 8225393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of heavy chain junctional amino acid diversity to antibody affinity among p-azophenylarsonate-specific antibodies.
    Parhami-Seren B; Margolies MN
    J Immunol; 1996 Sep; 157(5):2066-72. PubMed ID: 8757328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody.
    Winkler K; Kramer A; Küttner G; Seifert M; Scholz C; Wessner H; Schneider-Mergener J; Höhne W
    J Immunol; 2000 Oct; 165(8):4505-14. PubMed ID: 11035090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of antibody affinity by a non-contact residue.
    Schillbach JF; Near RI; Bruccoleri RE; Haber E; Jeffrey PD; Novotny J; Sheriff S; Margolies MN
    Protein Sci; 1993 Feb; 2(2):206-14. PubMed ID: 8443598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered hapten recognition by two anti-digoxin hybridoma variants due to variable region point mutations.
    Schildbach JF; Panka DJ; Parks DR; Jager GC; Novotny J; Herzenberg LA; Mudgett-Hunter M; Bruccoleri RE; Haber E; Margolies MN
    J Biol Chem; 1991 Mar; 266(7):4640-7. PubMed ID: 1999439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative analysis of the immunological evolution of antibody 28B4.
    Yin J; Mundorff EC; Yang PL; Wendt KU; Hanway D; Stevens RC; Schultz PG
    Biochemistry; 2001 Sep; 40(36):10764-73. PubMed ID: 11535051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody.
    Krause JC; Ekiert DC; Tumpey TM; Smith PB; Wilson IA; Crowe JE
    mBio; 2011; 2(1):e00345-10. PubMed ID: 21304166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural effects of framework mutations on a humanized anti-lysozyme antibody.
    Holmes MA; Buss TN; Foote J
    J Immunol; 2001 Jul; 167(1):296-301. PubMed ID: 11418663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction.
    Komissarov AA; Marchbank MT; Calcutt MJ; Quinn TP; Deutscher SL
    J Biol Chem; 1997 Oct; 272(43):26864-70. PubMed ID: 9341118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A molecular model of RGD ligands. Antibody D gene segments that direct specificity for the integrin alpha IIb beta 3.
    Tomiyama Y; Brojer E; Ruggeri ZM; Shattil SJ; Smiltneck J; Gorski J; Kumar A; Kieber-Emmons T; Kunicki TJ
    J Biol Chem; 1992 Sep; 267(25):18085-92. PubMed ID: 1517241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of antibody-antigen interaction through site-directed mutagenesis of the VH region of a hybrid phage-antibody fragment.
    Li Y; Owen MR; Cockburn W; Kumagai I; Whitelam GC
    Protein Eng; 1996 Dec; 9(12):1211-7. PubMed ID: 9010935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heavy chain CDR3 optimization of a germline encoded recombinant antibody fragment predisposed to bind the U1A protein.
    de Wildt RM; Ruytenbeek R; van Venrooij WJ; Hoet RM
    Protein Eng; 1997 Jul; 10(7):835-41. PubMed ID: 9342149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Site-directed mutagenesis of an invariant amino acid residue at the variable-diversity segments junction of an antibody.
    Sharon J; Gefter ML; Manser T; Ptashne M
    Proc Natl Acad Sci U S A; 1986 Apr; 83(8):2628-31. PubMed ID: 3085101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.